Founded in 1982, Britannia Pharmaceuticals Limited is a UK based pharmaceutical company specialising in the neurology market.
Our primary expertise is in the development and marketing of products in the area of Parkinson's disease.
Additionally we have developed non-opiate based therapeutics to assist in opiate detoxification and withdrawal, and have made advances in the areas of wound healing and respiratory disorders.
Britannia’s management team is comprised of experienced professionals with extensive knowledge of the pharmaceutical industry and drug development. We maintain close ties with key opinion leaders throughout the research and development process for each of our marketed products and those in development.
Britannia is owned by Frankfurt based STADA Arzneimttel AG.